LINICAL CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 408 JPY | +0.25% |
|
+1.75% | -23.40% |
ETFs positioned on Linical Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 19 M€ | +3.29% | ||
| 0.00% | 18 M€ | +16.15% | - | |
| 0.00% | 144,586 M€ | +13.90% | ||
| 0.00% | 66,066 M€ | +14.00% | - | |
| 0.00% | 20,721 M€ | +12.81% | - |
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
Calendar
2024-05-14
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
407
JPY
Average target price
500
JPY
Spread / Average Target
+22.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.40% | 59.28M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- 2183 Stock
- Funds and ETFs Linical Co., Ltd.
